Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Other Non Operating Income: 2009-2024

Historic Other Non Operating Income for Amicus Therapeutics (FOLD) over the last 15 years, with Dec 2024 value amounting to -$9.4 million.

  • Amicus Therapeutics' Other Non Operating Income rose 433.65% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 200.89%. This contributed to the annual value of -$9.4 million for FY2024, which is 40.57% up from last year.
  • As of FY2024, Amicus Therapeutics' Other Non Operating Income stood at -$9.4 million, which was up 40.57% from -$15.9 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Other Non Operating Income registered a high of $4.2 million during FY2022, and its lowest value of -$15.9 million during FY2023.
  • Moreover, its 3-year median value for Other Non Operating Income was -$9.4 million (2024), whereas its average is -$7.1 million.
  • As far as peak fluctuations go, Amicus Therapeutics' Other Non Operating Income skyrocketed by 243.95% in 2022, and later plummeted by 480.41% in 2023.
  • Over the past 5 years, Amicus Therapeutics' Other Non Operating Income (Yearly) stood at -$7.3 million in 2020, then surged by 60.13% to -$2.9 million in 2021, then spiked by 243.95% to $4.2 million in 2022, then plummeted by 480.41% to -$15.9 million in 2023, then soared by 40.57% to -$9.4 million in 2024.